Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.35 |
| ▸ | ITGAV | P06756 | 5/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.35 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | FBP1 | P09467 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7367618 | 1.00 | F2 (0.36) | F2ITGB3ITGAVITGA2BGLS | |
| SCHEMBL7366562 | 0.92 | F2 (0.36) | F2ITGB3ITGAVITGA2B | |
| SCHEMBL7366556 | 0.92 | F2 (0.36) | F2ITGB3ITGAVITGA2B | |
| SCHEMBL7377515 | 0.83 | ITGB3 (0.36) | F2ITGB3ITGAVITGA2BGLS | |
| SCHEMBL7377522 | 0.83 | ITGB3 (0.36) | F2ITGB3ITGAVITGA2BGLS | |
| SCHEMBL8177325 | 0.80 | ITGB3 (0.46) | F2ITGB3ITGAVITGA2B | |
| SCHEMBL8216119 | 0.77 | ITGB3 (0.39) | F2ITGB3ITGAVITGA2BGLS | |
| SCHEMBL7373174 | 0.75 | ITGB3 (0.43) | F2ITGB3ITGAVITGA2B | |
| SCHEMBL7373177 | 0.75 | ITGB3 (0.43) | F2ITGB3ITGAVITGA2B | |
| SCHEMBL8218081 | 0.72 | GLS (0.34) | F2ITGB3ITGAVITGA2BGLS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1049693-A1 | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999026945-A1 | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |